Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Terminated
1 enrolled 5 charts
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
13 enrolled 14 charts
SGI-110
Phase 2 Completed
120 enrolled 22 charts
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
81 enrolled 10 charts
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Terminated
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
Phase 2 Completed
75 enrolled
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Phase 2 Terminated
22 enrolled
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Phase 2 Terminated
6 enrolled 7 charts
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Phase 2 Completed
40 enrolled 10 charts
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Phase 2 Completed
194 enrolled
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Phase 2 Completed
18 enrolled 10 charts
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
Phase 2 Completed
80 enrolled
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Phase 2 Completed
77 enrolled 14 charts
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
Phase 2 Completed
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Phase 2 Completed
31 enrolled
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Phase 2 Completed
50 enrolled
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
Phase 2 Completed
165 enrolled
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2 Completed
Weekly Topotecan Therapy in Patients With Ovarian Cancer
Phase 2 Terminated
32 enrolled